
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3177454/publications.pdf Version: 2024-02-01



TAMADA MINKO

#	Article	IF	CITATIONS
1	Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2022, 21, 1381-1392.	1.9	0
2	Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opinion on Drug Delivery, 2021, 18, 205-227.	2.4	72
3	Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus. Advanced Therapeutics, 2021, 4, 2000203.	1.6	16
4	Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS Journal, 2021, 23, 14.	2.2	291
5	Loss-in-weight feeding, powder flow and electrostatic evaluation for direct compression hydroxypropyl methylcellulose (HPMC) to support continuous manufacturing. International Journal of Pharmaceutics, 2021, 596, 120259.	2.6	11
6	Multifunctional Lipid-Based Nanoparticles for Codelivery of Anticancer Drugs and siRNA for Treatment of Non-Small Cell Lung Cancer with Different Level of Resistance and EGFR Mutations. Pharmaceutics, 2021, 13, 1063.	2.0	29
7	Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier. Pharmaceutics, 2021, 13, 2049.	2.0	64
8	Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the â€~Undruggable' MYC in Pancreatic Cancer. Trends in Pharmacological Sciences, 2020, 41, 684-686.	4.0	29
9	Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation—Positive Lung Cancer Cells. Pharmaceutics, 2020, 12, 939.	2.0	15
10	Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery. Journal of Controlled Release, 2020, 326, 222-244.	4.8	52
11	Characterization of a novel hydroxypropyl methylcellulose (HPMC) direct compression grade excipient for pharmaceutical tablets. International Journal of Pharmaceutics, 2020, 583, 119343.	2.6	20
12	Nanocarrier-based systems for targeted and site specific therapeutic delivery. Advanced Drug Delivery Reviews, 2019, 144, 57-77.	6.6	171
13	On the plasticizing properties of divalproex sodium: physicochemical and spectroscopic characterization studies. Pharmaceutical Development and Technology, 2019, 24, 455-464.	1.1	4
14	Prevention of paclitaxel-induced neuropathy by formulation approach. Journal of Controlled Release, 2019, 303, 109-116.	4.8	28
15	Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy. Theranostics, 2019, 9, 8362-8376.	4.6	90
16	Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Delivery and Translational Research, 2018, 8, 1483-1507.	3.0	350
17	Evaluation of Affinisol® HPMC polymers for direct compression process applications. Journal of Drug Delivery Science and Technology, 2018, 47, 461-467.	1.4	14
18	Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer. Oncotarget, 2018, 9, 33249-33257.	0.8	6

#	Article	IF	CITATIONS
19	Nanoparticle design considerations for molecular imaging of apoptosis: Diagnostic, prognostic, and therapeutic value. Advanced Drug Delivery Reviews, 2017, 113, 122-140.	6.6	33
20	Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s). Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1983-1992.	1.7	52
21	LHRH-Targeted Drug Delivery Systems for Cancer Therapy. Mini-Reviews in Medicinal Chemistry, 2017, 17, 258-267.	1.1	49
22	Development of edge-activated liposomes for siRNA delivery to human basal epidermis for melanoma therapy. Journal of Controlled Release, 2016, 228, 150-158.	4.8	83
23	Precision targeted therapy of ovarian cancer. Journal of Controlled Release, 2016, 243, 250-268.	4.8	59
24	Nanotechnology approaches for inhalation treatment of lung diseases. Journal of Controlled Release, 2015, 219, 500-518.	4.8	258
25	Functionalized Mesoporous Silica Nanoparticles for Glucose―and pH‧timulated Release of Insulin. Zeitschrift Fur Anorganische Und Allgemeine Chemie, 2014, 640, 616-623.	0.6	18
26	Nanostructured TiO2 Catalyzed Oxidations of Caffeine and Isocaffeine and Their Cytotoxicity and Genotoxicity Towards Ovarian Cancer Cells. BioNanoScience, 2014, 4, 27-36.	1.5	9
27	Biodegradable Janus Nanoparticles for Local Pulmonary Delivery of Hydrophilic and Hydrophobic Molecules to the Lungs. Langmuir, 2014, 30, 12941-12949.	1.6	78
28	Delivery of antisense oligonucleotides using poly(alkylene oxide)–poly(propylacrylic acid) graft copolymers in conjunction with cationic liposomes. Journal of Controlled Release, 2014, 194, 103-112.	4.8	28
29	Dendritic Silica Nanomaterials (KCC-1) with Fibrous Pore Structure Possess High DNA Adsorption Capacity and Effectively Deliver Genes In Vitro. Langmuir, 2014, 30, 10886-10898.	1.6	88
30	Tumor-Targeted Responsive Nanoparticle-Based Systems for Magnetic Resonance Imaging and Therapy. Pharmaceutical Research, 2014, 31, 3487-3502.	1.7	43
31	Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention. Cancer Biology and Medicine, 2014, 11, 44-55.	1.4	88
32	Nanotechnology and drug resistance. Advanced Drug Delivery Reviews, 2013, 65, 1665-1666.	6.6	11
33	Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Advanced Drug Delivery Reviews, 2013, 65, 1880-1895.	6.6	133
34	Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. Journal of Controlled Release, 2013, 171, 349-357.	4.8	331
35	Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 335-344.	2.0	72
36	Nanotechnology approaches for inhalation treatment of fibrosis. Journal of Drug Targeting, 2013, 21, 914-925.	2.1	39

#	Article	IF	CITATIONS
37	Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: An Optimal Delivery of siRNA and Anticancer Drug. Clinical Cancer Research, 2013, 19, 6193-6204.	3.2	149
38	Genotoxicity of different nanocarriers: possible modifications for the delivery of nucleic acids. Current Drug Discovery Technologies, 2013, 10, 8-15.	0.6	53
39	Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases. Nanomedicine, 2012, 7, 185-197.	1.7	43
40	Receptor Mediated Delivery Systems for Cancer Therapeutics. , 2012, , 329-355.		6
41	Multifunctional Triblock Nanocarrier (PAMAM-PEG-PLL) for the Efficient Intracellular siRNA Delivery and Gene Silencing. ACS Nano, 2011, 5, 1877-1887.	7.3	184
42	Poly(propyleneimine) dendrimers as potential siRNA delivery nanocarrier: from structure to function. International Journal of Nanotechnology, 2011, 8, 36.	0.1	28
43	Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. Journal of Drug Targeting, 2011, 19, 900-914.	2.1	205
44	Multifunctional Nanomedicine Platform for Cancer Specific Delivery of siRNA by Superparamagnetic Iron Oxide Nanoparticles-Dendrimer Complexes. Current Drug Delivery, 2011, 8, 59-69.	0.8	137
45	Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. Journal of Controlled Release, 2011, 153, 16-22.	4.8	294
46	Non-viral systemic delivery of siRNA or antisense oligonucleotides targeted to Jun N-terminal kinase 1 prevents cellular hypoxic damage. Drug Delivery and Translational Research, 2011, 1, 13-24.	3.0	16
47	HPMA copolymers for modulating cellular signaling and overcoming multidrug resistanceâ~†. Advanced Drug Delivery Reviews, 2010, 62, 192-202.	6.6	29
48	Multifunctional Tumor-Targeted Polymer-Peptide-Drug Delivery System for Treatment of Primary and Metastatic Cancers. Pharmaceutical Research, 2010, 27, 2296-2306.	1.7	47
49	Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10737-10742.	3.3	162
50	LHRH-Targeted Nanoparticles for Cancer Therapeutics. Methods in Molecular Biology, 2010, 624, 281-294.	0.4	44
51	Labile Catalytic Packaging of DNA/siRNA: Control of Gold Nanoparticles "out―of DNA/siRNA Complexes. ACS Nano, 2010, 4, 3679-3688.	7.3	61
52	Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. Journal of Controlled Release, 2009, 140, 284-293.	4.8	305
53	Intratracheal Versus Intravenous Liposomal Delivery of siRNA, Antisense Oligonucleotides and Anticancer Drug. Pharmaceutical Research, 2009, 26, 382-394.	1.7	141
54	Coâ€delivery of Doxorubicin and Bclâ€2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrugâ€Resistant Cancer Cells. Small, 2009, 5, 2673-2677.	5.2	613

#	Article	IF	CITATIONS
55	Internally Cationic Polyamidoamine PAMAM-OH Dendrimers for siRNA Delivery: Effect of the Degree of Quaternization and Cancer Targeting. Biomacromolecules, 2009, 10, 258-266.	2.6	202
56	Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging?. Journal of Controlled Release, 2008, 130, 107-114.	4.8	218
57	Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine, 2008, 3, 761-776.	1.7	316
58	Surface-Modified and Internally Cationic Polyamidoamine Dendrimers for Efficient siRNA Delivery. Bioconjugate Chemistry, 2008, 19, 1396-1403.	1.8	196
59	Nonviral Nanoscale-Based Delivery of Antisense Oligonucleotides Targeted to Hypoxia-Inducible Factor 1α Enhances the Efficacy of Chemotherapy in Drug-Resistant Tumor. Clinical Cancer Research, 2008, 14, 3607-3616.	3.2	54
60	Targeted Proapoptotic Anticancer Drug Delivery System. Molecular Pharmaceutics, 2007, 4, 668-678.	2.3	60
61	Novel Polymeric Prodrug with Multivalent Components for Cancer Therapy. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 929-937.	1.3	78
62	Dendrimer Versus Linear Conjugate:Â Influence of Polymeric Architecture on the Delivery and Anticancer Effect of Paclitaxel. Bioconjugate Chemistry, 2006, 17, 1464-1472.	1.8	209
63	New Generation of Liposomal Drugs for Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2006, 6, 537-552.	0.9	83
64	Antibodies and Peptides in Cancer Therapy. Critical Reviews in Therapeutic Drug Carrier Systems, 2006, 23, 401-436.	1.2	35
65	Remediation of Cellular Hypoxic Damage by Pharmacological Agents. Current Pharmaceutical Design, 2005, 11, 3185-3199.	0.9	6
66	Soluble polymer conjugates for drug delivery. Drug Discovery Today: Technologies, 2005, 2, 15-20.	4.0	52
67	Drug targeting to the colon with lectins and neoglycoconjugates. Advanced Drug Delivery Reviews, 2004, 56, 491-509.	6.6	197
68	Enhancement of the Efficacy of Chemotherapy for Lung Cancer by Simultaneous Suppression of Multidrug Resistance and Antiapoptotic Cellular Defense. Cancer Research, 2004, 64, 6214-6224.	0.4	147
69	Targeted proapoptotic LHRH-BH3 peptide. Pharmaceutical Research, 2003, 20, 889-896.	1.7	73
70	Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharmaceutical Research, 2003, 20, 351-359.	1.7	91
71	HPMA copolymer–anticancer drug–OV-TL16 antibody conjugates. 3. The effect of free and polymer-bound Adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line. European Journal of Pharmaceutics and Biopharmaceutics, 2000, 49, 11-15.	2.0	32